Novocure Q3 2025 earnings Thursday, October 30, 2025 Confidential © 2024 © 2025 NovocuNovocu re GmbH re GmbH 1 forward -looking statements In addition to historical facts or statements of current condition, this presentation may contain forward - looking statements. Fo rward - looking statements provide Novocure's current expectations or forecasts of future events. These may include statements regarding anticipated scientific pro gress on its research programs, clinical trial progress, development of potent ...

Q3 2025 Performance Highlights - Total net revenue increased by 2% to $314 million compared to $307 million in Q3 2024[11] - SUBLOCADE net revenue increased by 15% to $219 million compared to $191 million in Q3 2024[11] - Adjusted EBITDA increased by 14% to $120 million compared to $105 million in Q3 2024[11] Financial Guidance Update - Total net revenue guidance raised to $1180 million - $1220 million, a 1% increase compared to previous guidance[34] - SUBLOCADE net revenue guidance raised to $825 million - $845 million, a 10% increase compared to previous guidance[34] - Adjusted EBITDA guidance raised to $400 million - $420 million, a 15% increase compared to previous guidance[34] Strategic Initiatives - The company is executing Phase I of the Indivior Action Agenda, focusing on generating momentum[13, 42] - Expect at least $150 million in Non-GAAP operating expense savings in 2026[17, 35] - U S SUBLOCADE YTD net revenue growth of 7% to $561 million compared to $524 million[17]

Company Overview - Nuvalent has a growing team of over 200 full-time employees (FTEs) and expects its cash runway to extend into 2028 [5] - The company has parallel lead programs for ROS1+ and ALK+ NSCLC in global clinical development, with potential for first FDA approval in 2026 [6] - Nuvalent leverages deep expertise in chemistry and structure-based drug design to maximize patient impact [7] Pipeline Programs - Zidesamtinib (NVL-520) is in an ongoing registration-directed Phase 2 trial for TKI-naïve and TKI pre-treated patients with ROS1+ NSCLC [16] - Neladalkib (NVL-655) is in an ongoing registration-directed Phase 2 trial for TKI pre-treated patients and an ongoing registration-directed Phase 3 trial for TKI-naïve patients with ALK+ NSCLC [16] - NVL-330 for HER2-altered NSCLC is in an ongoing Phase 1a/1b trial [16] Zidesamtinib (NVL-520) for ROS1+ NSCLC - In TKI pre-treated ROS1+ NSCLC, the ORR was 44% (51/117) across any prior ROS1 TKI and 51% (28/55) in patients with 1 prior ROS1 TKI [81] - Among TKI pre-treated patients with the ROS1 G2032R mutation, the ORR was 54% (14/26) [91] - In TKI-naïve ROS1+ NSCLC patients, the ORR was 89% (31/35) and the IC-ORR was 83% (5/6) [112] - 432 patients with ROS1-positive NSCLC were treated at the recommended Phase 2 dose (RP2D) as of March 21, 2025 [74] Neladalkib (NVL-655) for ALK+ NSCLC - In a heavily pre-treated ALK+ NSCLC population, the ORR was 38% (39/103) across all doses and 38% (15/39) at the RP2D [170] - Among patients with any ALK resistance mutation, the ORR at RP2D was 55% (12/22) [179] - For patients with compound ALK resistance mutations after prior lorlatinib, the ORR at RP2D was 64% (7/11) [179] - In ALK+ solid tumors beyond NSCLC, the overall ORR was 44% (15/34) [208] Market Opportunity - The combined worldwide sales for ALK and ROS1 TKIs in 2024 were approximately $3.1 billion [33] - Alectinib (1L Standard of Care, ALK+ NSCLC) sales were approximately $1.8 billion [34] - Crizotinib (1L Standard of Care, ROS1+ NSCLC) sales were $374 million in 2023 [34, 35] - Other ROS1 and ALK TKIs (Generally used 2L+) sales were approximately $1.2 billion [34]

Financial Performance - 3Q25 net income reached $12.8 million, resulting in an EPS of $0.77, marking an over 18% increase compared to 2Q25[13] - Year-to-date net income stands at $29.9 million, with an EPS of $1.80[13] - The FTE net interest margin (NIM) improved to 3.24% in 3Q25, compared to 3.16% in 2Q25[13] - Return on average assets (ROA) was 1.16% for 3Q25[13] - Tangible book value (TBV) per share increased by 2.7% from the previous quarter to $23.85[13] - The efficiency ratio improved to 59.6%[13] Balance Sheet and Capital Actions - Loan growth was 2% on an annualized basis[13] - Approximately $2 billion of deposits are subject to repricing with rate cuts[13] - The company repurchased $1.4 million worth of shares, totaling approximately 53,000 shares at an average cost of $26.87 per share[13] Credit Quality - Net charge-offs were 0.10% for 3Q25[13]

Financial Performance - Kimberly-Clark's Q3 2025 organic sales growth was 2.5% [48] - Adjusted operating profit growth for Q3 2025 was 0.1% [48] - Adjusted EPS growth attributable to Kimberly-Clark in Q3 2025 was (0.5%) [48] - Year-to-date adjusted free cash flow reached $1.263 billion [48] - The company is on track to achieve approximately $2 billion in adjusted free cash flow for the full year 2025 [48] Productivity and Savings - Q3 gross productivity reached 6.5% of adjusted COGS [12, 17] - Year-to-date gross productivity was 5.8% of adjusted COGS [17] - Kimberly-Clark is targeting the high end of 5-6% gross productivity savings in 2025 [19] Segment Performance - North America experienced organic growth of 2.1% year-to-date [22, 24] - International Personal Care saw organic growth of 2.1% in Q3 2025 [28] - International Personal Care volume+mix growth led by +5% volume growth in Focus Markets [30] Market Share - International Personal Care gained weighted share, with gains in Diapers & Pants [12] - Huggies market share increased by +230 bps in South Korea [30, 38] - Huggies market share increased by +90 bps in Brazil [30, 42]

Financial Performance - FY2025 H1 revenue decreased by 69% to JPY 22195 billion[21], a 39% decrease at CER[21] - FY2025 H1 core operating profit decreased by 112% to JPY 6392 billion[21], an 88% decrease at CER[21] - FY2025 H1 adjusted free cash flow increased by 1123% to JPY 5254 billion[21] - Growth & Launch Products increased by 53% at CER in H1[18, 24] - The company maintains broadly flat revenue guidance at CER[18, 36] Pipeline Update - Rusfertide and oveporexton are on track to file within FY2025[18] - Zasocitinib Ph3 psoriasis data is expected in H2[18] - Mezagitamab Ph1b IgAN data show durable eGFR over 18 months[18] - A partnership with Innovent Biologics to bolster the oncology pipeline[18] Oncology Partnership - Takeda entered into a license and collaboration agreement with Innovent Biologics for rights to IBI343 and IBI363, and an exclusive option to license rights to IBI3001, in each case worldwide outside of mainland China, Hong Kong, Macau and Taiwan[12] - IBI363 has demonstrated encouraging data across multiple solid tumor types, with a confirmed objective response rate (cORR) of 367% in sqNSCLC (IO-Refractory) and a median overall survival (mOS) of 153 months at 1/15 mg/kg[80] - IBI343 has shown robust monotherapy activity and a favorable safety profile, with a cORR of ~30% in 2L Pancreatic Cancer (CLDN182 1+/2+/3+ ≥60% expression) and an mOS of 121 months[94]

Q3 TRADING UPDATE 30 October 2025 2 Cautionary statement regarding forward- looking statements This document contains statements that are, or may be deemed to be, "forward-looking statements". Forward- looking statements give the Company's current expectations or forecasts of future events. These forward-looking statements may include, among other things, plans, objectives, beliefs, intentions, strategies, projections and anticipated future economic performance based on assumptions and the like that are sub ...

2025 Third quarter trading statement October 2025 Disclaimer This presentation contains certain statements that are, or may be deemed to be, "forward-looking statements" (including for purposes of the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934). Forward-looking statements give Haleon's current expectations and projections about future events, including strategic initiatives and future fin ...

3Q25 Earnings October 30, 2025 3Q25 EARNINGS Disclaimer This document is only provided for information purposes and is not intended to provide financial advice and, therefore, does not constitute, nor should it be interpreted as, an offer to sell, exchange or acquire, or an invitation for offers to acquire securities issued by any of the aforementioned companies, or to contract any financial product. Any decision to purchase or invest in securities or contract any financial product must be made solely and e ...

Financial Performance - The company reported a net profit of €6.1 billion [8] - Fee income reached €1,165 million, a 12% increase compared to 9M2024 [5] - Return on Equity was 12.6% [5] Commercial Growth - Mobile primary customers increased by 197,000 [5] - Net core lending grew by €14.2 billion [5] - Sustainable volume mobilised reached €110 billion for 9M2025 [5] Capital Management - The CET1 ratio stood at 13.4% [8] - A regular dividend of €3.1 billion was distributed [8] - Cash and share buybacks amounted to €4.5 billion [8] Outlook and Strategy - The company anticipates a return on equity exceeding 12.5% for the full year 2025 [58] - Total income for 2025 is projected to be approximately €22.8 billion [23]